07:00 , Jun 17, 2013 |  BC Week In Review  |  Company News

Zeria, Astellas sales and marketing update

Astellas launched Acofide acotiamide in Japan to treat functional dyspepsia. The National Health Insurance (NHI) list price is ¥36.20 ($0.37) per 100 mg tablet, which is given thrice daily. Japan's Ministry of Health, Labor...
07:00 , Apr 1, 2013 |  BC Week In Review  |  Clinical News

Acofide acotiamide regulatory update

Zeria and Astellas said Japan's Ministry of Health, Labor and Welfare (MHLW) approved Acofide acotiamide to treat functional dyspepsia. Astellas said it will launch the drug "promptly" after the price is established by Japan's National...
08:00 , Feb 18, 2013 |  BC Week In Review  |  Clinical News

Acotiamide regulatory update

Astellas said a Japanese advisory committee recommended approval of acotiamide to treat alcohol dependence. The company said a final decision from Japan's Ministry of Health, Labor and Welfare usually occurs 1-2 months after the committee...
07:00 , Jul 5, 2010 |  BC Week In Review  |  Clinical News

Acotiamide: Phase III data

In a double-blind, Japanese Phase III trial in 897 patients, thrice-daily 100 mg oral acotiamide met the co-primary endpoints of significantly improving general impression of FD symptoms as measured by a 7-point Likert scale and...
07:00 , Jul 5, 2010 |  BioCentury  |  Finance

2H10 milestones

2H10 milestones Selected products with Phase III or regulatory milestones expected in 2H10 Company Product Indication Event Milestone Actelion Ltd. (SIX:ATLN) Pivlaz clazosentan Prevent the occurrence...
08:00 , Mar 8, 2004 |  BioCentury  |  Strategy

The Fuji-Yama merger

The Fuji-Yama merger Product Indication Status Company Partner Rights (A) Vesicare solifenacin (YM905) Overactive bladder (OAB) Marketed (EU); approvable letter (U.S.) Yamanouchi GlaxoSmithKline U.S. co-promotion rights TRK-820 Dialysis-related uremic pruritis Under EU review...